Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTAXIM Booster Study in Argentinean Toddlers
NCT00303316Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Primary completion
- Apr 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Sanofi. Primary endpoints: Summary of Antibody Persistence at 18 Months of Age, Summary of Booster Response at Day 30 and 1 more. Started Feb 2006; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00303316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303316.